3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
5
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Sarcoma
32
Melanoma
10
Osteosarcoma
8
Neoplasm Metastasis
8
Sarcoma, Kaposi
6
Leiomyosarcoma
6
Histiocytoma, Malignant Fibrous
6
Chordoma
6
Gliosarcoma
5
Colorectal Neoplasms
5
Carcinosarcoma
5
Carcinoma, Transitional Cell
5
Carcinoma, Renal Cell
5
Carcinoma, Non-Small-Cell Lung
5
Carcinoma, Hepatocellular
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Sarcoma, Ewing
4
Neuroblastoma
4
Neoplasms
4
Bone Neoplasms
4
Rhabdomyosarcoma
3
Neurofibrosarcoma
3
Lung Neoplasms
3
Hemangiosarcoma
3
Glioblastoma
3
Gastrointestinal Stromal Tumors
3
Endometrial Neoplasms
3
Desmoid Tumors
3
Cholangiocarcinoma
3
Interventions
Magnetic Resonance Spectroscopy
15
Temozolomide
14
Radiotherapy
6
Filgrastim
6
Carmustine
6
Biopsy
6
X-Rays
5
Phantoms, Imaging
5
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
5
sargramostim
4
Specimen Handling
4
Peripheral Blood Stem Cell Transplantation
4
Nuclear Medicine Department, Hospital
4
Cyclophosphamide
4
olaparib
3
Thiotepa
3
Gadolinium DTPA
3
Cisplatin
3
Carboplatin
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
larotrectinib
2
ivosidenib
2
fluorodopa F 18
2
ensartinib
2
aldesleukin
2
Yoga
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ependymoma
×
Nivolumab
×
Sarcoma
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts